Latest Articlesddd

Radius Health: A New Osteoporosis Drug That Might Prevent Bone Fracture?

August 18, 2016 0

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is …

Why Portola Is Still Favorite

August 18, 2016 0

What’s Going on the Morning of Thursday, August 18, 2016? PORTOLA Portola Pharmaceuticals (PTLA) announced the …

Gilead and Genmab Agreement. A Quick Look at Moderna

August 15, 2016 0

GILEAD & GENMAB To Access Genmab’s (GEN) bispecific antibody technology, Gilead (GILD) signed a new agreement …

Editas, Adverum and Spark: Novel Gene Editing and Viral Vectors Make Gene Therapy Achievable

August 12, 2016 0

Gene Editing EDITAS MEDICINE CRISPR gene editing firm Editas Medicine (EDIT) signed a collaboration agreement with …

Sequenom: The Meaning of Becoming Part of LabCorp Holding

August 11, 2016 0

Sequenom (SQNM) is no more there as a separate biotech company, as it is on its …

Biotech Firms with Approaches Born To Stay and Succeed

August 10, 2016 0

Immunotherapy Engineered T-Cell Therapy Is Here to Stay Articles aimed at undermining the value of the …

Array: Selumetinib Negative Results Are No Match to Its Binimetinib Positive Results

August 9, 2016 0

We do expect some selling of Array today after AstraZeneca’s announced negative results from Phase 3 …

Why BMY News Is Not As Bad As Hysterical Investors Believed

August 5, 2016 0

ANOTHER MISLEADING STORY  This article was corrected after being posted. Read our apology at the end …

Plummeted Firms That Offer Good Investment Opportunities Are Filling the Place

August 3, 2016 0

Investors in the stock market know that stocks yo-yo all the time. Sometimes, the yo-yoing becomes …

Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

August 1, 2016 0

EMA’s created Priority Medicines (PRIME) regulatory initiative for products which the European agency rules they are …

Answering Readers Questions About the Possible Outcome of Valeant Pharmaceuticals’ Psoriasis Drug

July 19, 2016 0

The FDA advisory committee members’ inability to rule for or against the approval of Valeant (VRX) …

Coming from AstraZeneca and Juno: News That Makes a Big Difference

July 18, 2016 0

Important news is the news that informs about successful achievements that make a difference in treating …

NOVOCURE: The FDA Approves the Firm’s Second Generation Non-Invasive Treatment for Glioblastoma

July 15, 2016 0

News about approvals or insinuations about almost guaranteed future approvals of products that promise improving the …

The FDA Approves INSIGHTEC’s Non-Invasive Approach That Treats Tremors. Humans Can Make Miracles Too.

July 15, 2016 0

The FDA approved INSIGHTEC firm’s Exablate Neuro system for the non-invasive treatment of essential tremor (ET) …

JUNO Surged After the FDA Removed the Clinical Hold of the ROCKET Trial. See Also: Why SAGE Surged

July 13, 2016 0

JUNO   Juno Therapeutics (JUNO), the CAR T developing firm that aims at revolutionizing cancer treatment …

Why Amgen Is Still King. Why Roche Allergic Asthma Drug Xolair Is Becoming a Blockbuster.

July 11, 2016 0

AMGEN Repatha is the human monoclonal antibody that blocks a protein called proprotein convertase subtilisin/kexin type …

JUNO: The CAR-T Approach Is Still a Source of Hope for Cancer Patients Who Have Lost It

July 8, 2016 0

Juno Therapeutics (JUNO) announced that the U.S. Food and Drug Administration (FDA) has placed a clinical …

Biotech Firms with Guaranteed Growth Potential

July 7, 2016 0

Good news is not always great news that makes a difference. In the drug industry, clinical …

Oncolytic Adenovirus Plus Opdivo Could Be a Game Changer in Late Stage Cancer. See Also: Gossip Surrounds Tesaro

July 5, 2016 0

PsiOxus Therapeutics’ adenovirus product in combination with Opdivo (nivo-lumab) for late-stage cancers.     Bristol-Myers Squibb (BMY) …

Tesaro: The Time Has Come for Bringing Hope to Recurrent Ovarian Cancer Patients

July 1, 2016 0

- Tesaro's (TSRO) drug niraparib significantly improved progression-free survival for patients with ovarian cancer in both …